Prostaglandins and cancer

D. Wang, R. N. Dubois

Research output: Contribution to journalReview article

620 Scopus citations

Abstract

Chemoprevention has been considered as a possible approach for cancer prevention. A significant effort has been made in the development of novel drugs for both cancer prevention and treatment over the past decade. Recent epidemiological studies and clinical trials indicate that long term use of aspirin and similar agents, also called non-steroidal anti-inflammatory drugs (NSAIDs), can decrease the incidence of certain malignancies, including colorectal, oesophageal, breast, lung, and bladder cancers. The best known targets of NSAIDs are cyclooxygenase (COX) enzymes, which convert arachidonic acid to prostaglandins (PGs) and thromboxane. COX-2 derived prostaglandin E 2 (PGE2) can promote tumour growth by binding its receptors and activating signalling pathways which control cell proliferation, migration, apoptosis, and/or angiogenesis. However, the prolonged use of high dosages of COX-2 selective inhibitors (COXIBs) is associated with unacceptable cardiovascular side effects. Thus it is crucial to develop more effective chemopreventive agents with minimal toxicity. Recent efforts to identify the molecular mechanisms by which PGE2 promotes tumour growth and metastasis may provide opportunities for the development of safer strategies for cancer prevention and treatment.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalGut
Volume55
Issue number1
DOIs
StatePublished - Jan 2006

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Prostaglandins and cancer'. Together they form a unique fingerprint.

  • Cite this

    Wang, D., & Dubois, R. N. (2006). Prostaglandins and cancer. Gut, 55(1), 115-122. https://doi.org/10.1136/gut.2004.047100